Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 19, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback:
- Shares Purchased: 600,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,206.53 pence per share.
- Treasury Holdings: 474,194,158 shares (representing 9.11% of total voting rights).
- Shares in Issue: 5,206,597,162 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 600,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158, while the total shares in issue remain at 5,206,597,162.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 600,000 share repurchase (600,000 shares x 1,206.53 pence).
- Confirm the updated Treasury share count of 474,194,158 against subsequent filings.
- Review the impact of the 9.11% Treasury holding on total voting rights calculations.
- Check the remaining authorization for share buybacks under the May 21, 2008 shareholder mandate.